Home › Opko Health Submits Claros 1 Prostate Cancer Test, Immunoassay System for FDA Approval

Opko Health Submits Claros 1 Prostate Cancer Test, Immunoassay System for FDA Approval

Nov 07, 2017

NEW YORK (360Dx) – Opko Health today announced the filing of a premarket approval application with the US Food and Drug Administration for a total prostate-specific antigen test with the firm's Claros 1 immunoassay analyzer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
14
Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19
Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
28
Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

What's Popular?

In Diagnostics

  1. Novitas Issues Draft LCD for Non-Coverage of Opko's 4Kscore Prostate Cancer Test

  2. Boca Biolistics Expands Into Reference Lab Services

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.